A New Paradigm for Pediatric AML: Improving the Pipeline for Treatments Targeting Cytogenetic and Molecular Alterations.
This review synthesizes high-risk cytogenetic and molecular alterations in pediatric AML and discusses integrating alteration-directed agents, including FLT3 and menin inhibitors, into frontline treatment and pediatric clinical-trial pipelines.
Open original publication →What the AI sees
This review synthesizes high-risk cytogenetic and molecular alterations in pediatric AML and discusses integrating alteration-directed agents, including FLT3 and menin inhibitors, into frontline treatment and pediatric clinical-trial pipelines.
Research significance
The supplied record supports genotype-guided risk stratification and identifies targeted therapies already emerging in AML; it is reasonable—but not demonstrated here—to hypothesize that matching pediatric patients to agents such as FLT3 or menin inhibitors and evaluating them earlier in treatment could improve outcomes in genetically defined high-risk subgroups.
Source abstract
Pediatric acute myeloid leukemia (AML) is a highly heterogeneous malignancy, with cytogenetic and molecular abnormalities playing a critical role in determining prognosis and guiding treatment decisions. Despite therapeutic advances, patients with high-risk genetic mutations and translocations continue to experience suboptimal outcomes. As new targeted therapies emerge, the treatment of pediatric AML could undergo a paradigm shift, where "one-size-fits-all" chemotherapy is no longer the only frontline approach. Identifying genetic markers inform risk stratification and have greater impact on shaping the therapeutic approach, including the integration of targeted therapies such as FLT3 and menin inhibitors into frontline therapy. Furthermore, pediatric AML treatment options are being driven by recent discoveries in adult AML, broadening their clinical trials to include pediatric patients, in part due to the RACE for Children Act that went into effect in August 2020. This review identifies the most prevalent high-risk cytogenetic lesions in pediatric AML, emphasizing their incidence, prognostic significance, and implications for clinical management. By synthesizing current research on these key genetic abnormalities and their associated therapies, we aim to provide an updated perspective on the evolving landscape of high-risk pediatric AML management that can then lead to the establishment of an agile framework to rapidly evaluate, approve, and deploy novel agents.